Phase 2A Study as an Open Label, Multiple Ascending Dose With Randomized Subjects to Receive a Single Dose of One of Three Dose Levels
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2018
At a glance
- Drugs Risperidone (Primary) ; Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Reckitt Benckiser
- 21 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 06 Sep 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 11 Sep 2012 New trial record